LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1963 | 3694 | 0.5316 | 0.2196 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1954 | 3694 | 0.5291 | 0.2156 |
| SK-BR-3 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 1476 | 4054 | 3694 | 1.0975 | 1.1625 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3282 | 3694 | 0.8886 | 0.8145 |
| SK-BR-3 | Foretinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1454 | 3694 | 0.3938 | -0.0099 |
| SK-BR-3 | R406 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 4165 | 3694 | 1.1276 | 1.2125 |
| SK-BR-3 | Pictilisib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1669 | 3694 | 0.4518 | 0.0867 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2026 | 3694 | 0.5485 | 0.2479 |
| SK-BR-3 | Geldanamycin | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1345 | 3694 | 0.3641 | -0.0594 |
| SK-BR-3 | Geldanamycin | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1193 | 3694 | 0.3230 | -0.1280 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1010 | 3694 | 0.2734 | -0.2105 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1137 | 3694 | 0.3079 | -0.1531 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 1476 | 3691 | 3694 | 0.9993 | 0.9988 |
| SK-BR-3 | Omipalisib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1048 | 3694 | 0.2838 | -0.1932 |
| SK-BR-3 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2884 | 3694 | 0.7809 | 0.6350 |
| SK-BR-3 | GW843682X | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1194 | 3694 | 0.3234 | -0.1272 |
| SK-BR-3 | HG-5-113-01 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1177 | 3694 | 0.3188 | -0.1349 |
| SK-BR-3 | HG-5-88-01 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2638 | 3694 | 0.7143 | 0.5240 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 4092 | 3694 | 1.1078 | 1.1796 |
| SK-BR-3 | JNK-9L | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1380 | 3694 | 0.3736 | -0.0436 |
| SK-BR-3 | JW-7-24-1 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2056 | 3694 | 0.5568 | 0.2616 |
| SK-BR-3 | Lapatinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1542 | 3694 | 0.4174 | 0.0294 |
| SK-BR-3 | LDN-193189 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1055 | 3694 | 0.2857 | -0.1900 |
| SK-BR-3 | Linifanib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 4062 | 3694 | 1.0996 | 1.1659 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2842 | 3694 | 0.7694 | 0.6157 |